Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Alkermes has announced early-stage trial data suggesting its orexin agonist could treat attention deficit hyperactivity disorder. Both Fierce Biotech and STAT describe the results as a first for the drug class, which has previously been tied to sleep disorders.
The news comes after Takeda won approval for Orzeyful, the first orexin agonist, as a narcolepsy treatment. Fierce Biotech frames Alkermes' data as a potential "company changer" that could move the class into broader patient populations, while STAT notes the therapy showed potential in an early-stage study.
The two reports agree on the core significance: orexin agonists may offer a new mechanism for ADHD. However, neither source provides details on effect size or safety, and both imply that larger, later-stage trials will be necessary to validate the early promise.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.
Novo Nordisk seeks to reassure investors with new drug pipeline
At a capital markets day, Novo's CEO acknowledged investor doubts and outlined plans to compete with Eli Lilly and launch several multibillion-dollar products.